Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Interest Expenses (2022 - 2025)

Historic Interest Expenses for Arrowhead Pharmaceuticals (ARWR) over the last 4 years, with Q4 2025 value amounting to $22.5 million.

  • Arrowhead Pharmaceuticals' Interest Expenses rose 396.84% to $22.5 million in Q4 2025 from the same period last year, while for Dec 2025 it was $90.2 million, marking a year-over-year increase of 8551.95%. This contributed to the annual value of $89.4 million for FY2025, which is 17621.48% up from last year.
  • Latest data reveals that Arrowhead Pharmaceuticals reported Interest Expenses of $22.5 million as of Q4 2025, which was up 396.84% from $21.7 million recorded in Q3 2025.
  • Arrowhead Pharmaceuticals' Interest Expenses' 5-year high stood at $24.4 million during Q2 2025, with a 5-year trough of $2.8 million in Q4 2022.
  • Its 4-year average for Interest Expenses is $12.5 million, with a median of $7.2 million in 2024.
  • In the last 5 years, Arrowhead Pharmaceuticals' Interest Expenses tumbled by 124.08% in 2024 and then soared by 37864.15% in 2025.
  • Quarter analysis of 4 years shows Arrowhead Pharmaceuticals' Interest Expenses stood at $2.8 million in 2022, then skyrocketed by 88.38% to $5.4 million in 2023, then skyrocketed by 303.32% to $21.6 million in 2024, then rose by 3.97% to $22.5 million in 2025.
  • Its Interest Expenses stands at $22.5 million for Q4 2025, versus $21.7 million for Q3 2025 and $24.4 million for Q2 2025.